Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Wanner

Showing results (591-600 of 666) with videos related to

Pageof 67
Sort By:
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 13, 2015
The changing trends and outcomes in renal replacement therapy: data from the ERA-EDTA RegistryMaria Pippias, Kitty J Jager, Anneke Kramer, et al.
Nature Communications|January 10, 2026
Lucerastat, an oral therapy for Fabry disease: results from a pivotal randomized phase 3 study and its open-label extensionPeter Nordbeck, Ozlem Goker-Alpan, John A Bernat, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 19, 2025
ABCDE to identify and prevent chronic kidney disease: a call to actionCharles J Ferro, Christoph Wanner, Valerie Luyckx, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 3, 2025
Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY TrialKaitlin J Mayne, Rebecca J Sardell, Natalie Staplin, et al.
European Heart Journal|August 8, 2015
Serum amyloid A: high-density lipoproteins interaction and cardiovascular riskStephen Zewinger, Christiane Drechsler, Marcus E Kleber, et al.
Circulation. Cardiovascular Genetics|September 20, 2013
Genome-wide association study identifies 3 genomic loci significantly associated with serum levels of homoarginine: the AtheroRemo ConsortiumMarcus E Kleber, Ilkka Seppälä, Stefan Pilz, et al.
JAMA Network Open|April 18, 2022
Trends in Mortality Due to Myocardial Infarction, Stroke, and Pulmonary Embolism in Patients Receiving DialysisGurbey Ocak, Rianne Boenink, Marlies Noordzij, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 1, 2024
Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trialKaitlin J Mayne, Rebecca J Sardell, Natalie Staplin, et al.
Clinical Kidney Journal|February 11, 2021
A roadmap for optimizing chronic kidney disease patient care and patient-oriented research in the Eastern European nephrology communityMehmet Şükrü Sever, Kitty J Jager, Raymond Vanholder, et al.
The American Journal of Cardiology|December 17, 2008
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemiaJean-Charles Fruchart, Frank Sacks, Michel P Hermans, et al.
Pageof 67

Showing results (591-600 of 666) with videos related to

Sort By:
Pageof 67
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 13, 2015
The changing trends and outcomes in renal replacement therapy: data from the ERA-EDTA RegistryMaria Pippias, Kitty J Jager, Anneke Kramer, et al.
Nature Communications|January 10, 2026
Lucerastat, an oral therapy for Fabry disease: results from a pivotal randomized phase 3 study and its open-label extensionPeter Nordbeck, Ozlem Goker-Alpan, John A Bernat, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 19, 2025
ABCDE to identify and prevent chronic kidney disease: a call to actionCharles J Ferro, Christoph Wanner, Valerie Luyckx, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 3, 2025
Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY TrialKaitlin J Mayne, Rebecca J Sardell, Natalie Staplin, et al.
European Heart Journal|August 8, 2015
Serum amyloid A: high-density lipoproteins interaction and cardiovascular riskStephen Zewinger, Christiane Drechsler, Marcus E Kleber, et al.
Circulation. Cardiovascular Genetics|September 20, 2013
Genome-wide association study identifies 3 genomic loci significantly associated with serum levels of homoarginine: the AtheroRemo ConsortiumMarcus E Kleber, Ilkka Seppälä, Stefan Pilz, et al.
JAMA Network Open|April 18, 2022
Trends in Mortality Due to Myocardial Infarction, Stroke, and Pulmonary Embolism in Patients Receiving DialysisGurbey Ocak, Rianne Boenink, Marlies Noordzij, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 1, 2024
Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trialKaitlin J Mayne, Rebecca J Sardell, Natalie Staplin, et al.
Clinical Kidney Journal|February 11, 2021
A roadmap for optimizing chronic kidney disease patient care and patient-oriented research in the Eastern European nephrology communityMehmet Şükrü Sever, Kitty J Jager, Raymond Vanholder, et al.
The American Journal of Cardiology|December 17, 2008
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemiaJean-Charles Fruchart, Frank Sacks, Michel P Hermans, et al.
Pageof 67